10-QPeriod: Q3 FY2021

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2021

Filed November 4, 2021For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported a strong third quarter for 2021, demonstrating significant revenue and profit growth driven by robust performance across its key products. Total revenues increased by 55% year-over-year to $3.45 billion, with net product sales growing substantially, notably from EYLEA and Dupixent. The company also saw a significant boost from REGEN-COV, its COVID-19 antibody treatment, which contributed substantially to revenue in the period. Net income rose by an impressive 94% to $1.63 billion, translating to diluted earnings per share of $14.33, a significant increase from the prior year. This strong financial performance reflects the company's expanding commercial reach and the continued success of its late-stage pipeline. Looking ahead, Regeneron's pipeline remains robust, with several key products in advanced clinical development and ongoing regulatory reviews. The company's strategic collaborations, particularly with Sanofi and Bayer, continue to drive significant revenue. Management's focus remains on advancing its broad pipeline of innovative therapies while strategically deploying capital, including ongoing share repurchase programs, to enhance shareholder value. Investors should monitor the company's progress in key therapeutic areas and the impact of ongoing research and development efforts on future growth.

Financial Highlights

46 data points
Beta

Revenue

$3.45B

Net Income

$1.63B

47.3% Net Margin

EPS (Diluted)

$14.33

Total Assets

$23.67B

Cash & Equivalents

$3.44B

Free Cash Flow

$3.41B

Financial Statements
Beta
Revenue$3.45B
R&D Expenses$665.40M
SG&A Expenses$445.00M
Operating Expenses$1.61B
Operating Income$1.85B
Interest Expense$14.20M
Net Income$1.63B
EPS (Basic)$15.37
EPS (Diluted)$14.33
Shares Outstanding (Basic)106.20M
Shares Outstanding (Diluted)113.90M

Key Highlights

  • 1Total revenues surged by 55% year-over-year to $3.45 billion for the third quarter of 2021.
  • 2Net income increased by 94% to $1.63 billion, with diluted EPS of $14.33.
  • 3Significant growth in net product sales was observed for EYLEA (+15%) and Dupixent (+55%), demonstrating continued market strength.
  • 4REGEN-COV contributed $676.7 million in net product sales in the U.S. during the quarter, reflecting its importance in COVID-19 treatment.
  • 5Collaboration revenue from Sanofi increased by 65% to $581.8 million, driven by strong performance in the Antibody Collaboration.
  • 6The company repurchased approximately $190.5 million of its common stock during the quarter under its authorized share repurchase program.
  • 7Cash and cash equivalents increased significantly to $3.43 billion as of September 30, 2021.

Frequently Asked Questions

Regeneron's key revenue drivers in Q3 2021 were strong net product sales from EYLEA and Dupixent, which showed significant year-over-year growth. Additionally, REGEN-COV, the company's COVID-19 antibody treatment, was a major contributor to revenue during the quarter.

Regeneron's profitability saw substantial improvement, with net income increasing by 94% to $1.63 billion in Q3 2021, compared to $842.1 million in the same period of 2020. Diluted earnings per share also increased significantly to $14.33 from $7.39.

Regeneron has an active share repurchase program. As of September 30, 2021, approximately $697.3 million remained available for future repurchases under the $1.5 billion program authorized in January 2021. The company repurchased $190.5 million of its common stock in the third quarter.

Yes, Regeneron has significant collaborations that impact its financial results. The collaboration with Sanofi for antibodies (Dupixent, Kevzara, itepekimab) and immuno-oncology products (Libtayo) continues to be a major revenue driver. The collaboration with Bayer for EYLEA outside the United States also contributes significantly to revenue.